IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,456 shares of the company’s stock after acquiring an additional 526 shares during the period. Motley Fool Asset Management LLC’s holdings in IDEXX Laboratories were worth $1,842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Public Sector Pension Investment Board lifted its holdings in shares of IDEXX Laboratories by 16.2% during the third quarter. Public Sector Pension Investment Board now owns 3,578 shares of the company’s stock worth $1,808,000 after purchasing an additional 500 shares during the period. Verition Fund Management LLC lifted its stake in IDEXX Laboratories by 20.5% during the 3rd quarter. Verition Fund Management LLC now owns 6,508 shares of the company’s stock valued at $3,288,000 after acquiring an additional 1,108 shares during the period. Benjamin Edwards Inc. boosted its holdings in shares of IDEXX Laboratories by 661.1% in the 3rd quarter. Benjamin Edwards Inc. now owns 1,880 shares of the company’s stock valued at $950,000 after acquiring an additional 1,633 shares during the last quarter. Centiva Capital LP acquired a new stake in shares of IDEXX Laboratories in the third quarter worth $211,000. Finally, Janus Henderson Group PLC raised its holdings in shares of IDEXX Laboratories by 0.4% during the third quarter. Janus Henderson Group PLC now owns 11,834 shares of the company’s stock worth $5,978,000 after purchasing an additional 53 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $410.76 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The stock has a market capitalization of $33.30 billion, a PE ratio of 38.50, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The company has a fifty day moving average of $436.39 and a two-hundred day moving average of $441.13.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on IDXX. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, March 25th. Bank of America boosted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Barclays raised their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Finally, Piper Sandler raised their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.